^
    Back
    Association details:
    Biomarker:BMI1 expression
    Cancer:Multiple Myeloma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2018
    Title:

    SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA

    Published date:
    05/17/2018
    Excerpt:
    101 bone marrow (BM) aspirates were collected from 32 newly diagnosed and 51 relapsed myeloma patients...CCND1 and BMI1 expression correlated with sensitivity to BCL2 inhibitor venetoclax.